Focus Partners Advisor Solutions LLC Raises Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Focus Partners Advisor Solutions LLC grew its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 125.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,583 shares of the medical research company's stock after acquiring an additional 2,548 shares during the quarter. Focus Partners Advisor Solutions LLC's holdings in Thermo Fisher Scientific were worth $2,385,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Cypress Advisory Group LLC purchased a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth about $253,000. Intact Investment Management Inc. raised its holdings in Thermo Fisher Scientific by 34.0% in the 4th quarter. Intact Investment Management Inc. now owns 2,600 shares of the medical research company's stock valued at $1,353,000 after acquiring an additional 660 shares during the last quarter. Purkiss Capital Advisors LLC purchased a new position in shares of Thermo Fisher Scientific during the 4th quarter worth $1,121,000. Fifth Third Bancorp grew its position in shares of Thermo Fisher Scientific by 11.6% in the fourth quarter. Fifth Third Bancorp now owns 335,053 shares of the medical research company's stock valued at $174,305,000 after purchasing an additional 34,917 shares during the period. Finally, Independence Bank of Kentucky increased its stake in Thermo Fisher Scientific by 21.0% in the fourth quarter. Independence Bank of Kentucky now owns 3,825 shares of the medical research company's stock valued at $1,990,000 after purchasing an additional 663 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company's stock.

Thermo Fisher Scientific Stock Down 3.8%

Shares of Thermo Fisher Scientific stock opened at $397.89 on Thursday. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59. The business has a 50-day moving average price of $447.48 and a 200 day moving average price of $507.46. Thermo Fisher Scientific Inc. has a fifty-two week low of $390.50 and a fifty-two week high of $627.88. The firm has a market cap of $150.20 billion, a P/E ratio of 24.07, a P/E/G ratio of 2.99 and a beta of 0.82.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.10 by $0.05. The firm had revenue of $10.36 billion for the quarter, compared to analysts' expectations of $10.23 billion. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. The firm's revenue for the quarter was up .2% on a year-over-year basis. During the same period last year, the business posted $5.11 earnings per share. On average, sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, July 15th. Shareholders of record on Friday, June 13th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 0.43%. Thermo Fisher Scientific's payout ratio is currently 10.09%.

Analyst Upgrades and Downgrades

TMO has been the topic of several recent analyst reports. Raymond James reiterated an "outperform" rating and set a $667.00 price objective (up from $650.00) on shares of Thermo Fisher Scientific in a report on Monday, February 3rd. Citigroup dropped their price objective on Thermo Fisher Scientific from $650.00 to $570.00 and set a "neutral" rating for the company in a report on Tuesday, March 4th. Scotiabank reduced their target price on Thermo Fisher Scientific from $650.00 to $605.00 and set a "sector perform" rating on the stock in a report on Friday, April 25th. Barclays decreased their target price on Thermo Fisher Scientific from $620.00 to $475.00 and set an "equal weight" rating for the company in a report on Thursday, April 10th. Finally, Robert W. Baird reduced their price target on shares of Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating on the stock in a research report on Thursday, April 24th. Four equities research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $607.43.

Insider Activity

In related news, SVP Michael A. Boxer sold 3,775 shares of the company's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the completion of the transaction, the senior vice president now directly owns 10,816 shares in the company, valued at $5,759,736.32. This represents a 25.87% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the firm's stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $516.67, for a total value of $5,166,700.00. Following the completion of the sale, the chief executive officer now owns 115,174 shares in the company, valued at $59,506,950.58. The trade was a 7.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 14,075 shares of company stock valued at $7,305,942. 0.33% of the stock is currently owned by insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.